First National Bank of Mount Dora Trust Investment Services grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,176 shares of the company’s stock after buying an additional 1,350 shares during the quarter. Johnson & Johnson accounts for approximately 3.4% of First National Bank of Mount Dora Trust Investment Services’ holdings, making the stock its 2nd biggest holding. First National Bank of Mount Dora Trust Investment Services’ holdings in Johnson & Johnson were worth $6,914,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. grew its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. State Street Corp grew its holdings in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. FMR LLC grew its holdings in Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors grew its holdings in Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after acquiring an additional 1,050,000 shares during the last quarter. Institutional investors own 65.70% of the company’s stock.
A number of equities research analysts have commented on the stock. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective on the stock. in a report on Monday. JPMorgan Chase & Co. lowered shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. BMO Capital Markets increased their price objective on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $145.52.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.68 EPS. equities research analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.32%. Johnson & Johnson’s dividend payout ratio is 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.